Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Clinical Medicine (London, England)
|
March 11, 2009
Public health issues with counterfeit medicines
Peter Feldschreiber
Clinical Pharmacology and Therapeutics
|
October 23, 2018
Impact of Brexit on UK and EU Drug Regulation and Patient Access
Alasdair Breckenridge, Peter Feldschreiber
British Journal of Clinical Pharmacology
|
June 7, 2013
Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines
John D Johnston, Peter Feldschreiber
Clinical Pharmacology and Therapeutics
|
June 26, 2019
Response to "Medicines Shortages in the United Kingdom"
Alasdair Breckenridge, Peter Feldschreiber
Reviews on Recent Clinical Trials
|
May 1, 2015
After thalidomide - do we have the right balance between public health and intellectual property
Peter Feldschreiber, Alasdair Breckenridge
British Journal of Clinical Pharmacology
|
April 23, 2014
Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products
John D Johnston, Peter Feldschreiber
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
The Imperfect Intellectual Bridge Between a Master Medicinal Product and Its Associated Custom-Made Medicinal Products
John D Johnston, Peter Feldschreiber
British Journal of Sports Medicine
|
June 7, 2011
Medicolegal neglect? The case for physical activity promotion and exercise medicine
Richard Weiler, Peter Feldschreiber, Emmanuel Stamatakis
British Journal of Clinical Pharmacology
|
March 13, 2012
Symmetrical analysis of risk-benefit
John B Warren, Simon Day, Peter Feldschreiber
British Journal of Clinical Pharmacology
|
July 23, 2014
The medico-legal aspects of prescribing vitamin D
John S Davies, Chris D Poole, Peter Feldschreiber
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Clinical Medicine (London, England)
|
March 11, 2009
Public health issues with counterfeit medicines
Peter Feldschreiber
Clinical Pharmacology and Therapeutics
|
October 23, 2018
Impact of Brexit on UK and EU Drug Regulation and Patient Access
Alasdair Breckenridge, Peter Feldschreiber
British Journal of Clinical Pharmacology
|
June 7, 2013
Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines
John D Johnston, Peter Feldschreiber
Clinical Pharmacology and Therapeutics
|
June 26, 2019
Response to "Medicines Shortages in the United Kingdom"
Alasdair Breckenridge, Peter Feldschreiber
Reviews on Recent Clinical Trials
|
May 1, 2015
After thalidomide - do we have the right balance between public health and intellectual property
Peter Feldschreiber, Alasdair Breckenridge
British Journal of Clinical Pharmacology
|
April 23, 2014
Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products
John D Johnston, Peter Feldschreiber
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
The Imperfect Intellectual Bridge Between a Master Medicinal Product and Its Associated Custom-Made Medicinal Products
John D Johnston, Peter Feldschreiber
British Journal of Sports Medicine
|
June 7, 2011
Medicolegal neglect? The case for physical activity promotion and exercise medicine
Richard Weiler, Peter Feldschreiber, Emmanuel Stamatakis
British Journal of Clinical Pharmacology
|
March 13, 2012
Symmetrical analysis of risk-benefit
John B Warren, Simon Day, Peter Feldschreiber
British Journal of Clinical Pharmacology
|
July 23, 2014
The medico-legal aspects of prescribing vitamin D
John S Davies, Chris D Poole, Peter Feldschreiber
Page
of 2